CommercialCoverageHigh impact
Indications, Dosages and Administration of FDA-Approved Drugs (CPB 0156, reviewed 2026-04-23)
Aetna·Pharmacy·Pharmacy
We identified it
Aug 15, 2026
Summary
Aetna updated its foundational pharmacy policy (CPB 0156) establishing the hierarchy of evidence sources for determining medical necessity of FDA-approved drugs when no specific Aetna policy exists. The policy clarifies that coverage decisions rely on: CVS Caremark policies, FDA labeling, established pharmacy compendia (AHFS, Micromedex, Clinical Pharmacology, UpToDate Lexidrug, NCCN), or well-designed Phase III/IIb clinical trials. This is a reference framework policy that affects how all drug coverage determinations are made across Aetna commercial plans.
Action Required
BILLING & CLINICAL TEAMS ACTION REQUIRED: This is a framework policy effective immediately (reviewed 2026-04-23). No immediate workflow changes are mandated, but all staff must understand the new evidence hierarchy for drug coverage appeals and prior authorization denials: (1) Billing team: When claims are denied for lack of medical necessity on FDA-approved drugs, reference this policy hierarchy in appeals—cite CVS Caremark policies, FDA labeling, compendia evidence (AHFS, Micromedex, Clinical Pharmacology, UpToDate Lexidrug, NCCN), or published Phase III/IIb trials. (2) Providers & Clinical staff: When prescribing FDA-approved drugs not covered by specific Aetna policies, ensure documentation references one of these four evidence sources to support medical necessity. (3) Appeals/Authorization staff: Update denial letter templates and appeal processes to reference CPB 0156 when challenging coverage denials—this policy legitimizes appeals based on compendia or peer-reviewed evidence. Failure to cite appropriate evidence sources may result in continued claim denials and lost revenue on legitimate off-label or less-common drug indications.